Scientists test new ways to deliver vaccines through nose and mouth

NCT ID NCT00820144

Completed Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Nice Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study in 40 healthy adults explores how the immune system reacts to the non-toxic part of cholera toxin (CTB) when given through the nose, mouth, or under the tongue. The goal is to understand mucosal immune responses, which could help in developing future vaccines that are easier to take. No direct benefit is expected for participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cholera toxin B-subunit (CTB)
What this could lead to: If successful, this research could help design better vaccines that are given through the nose or mouth instead of by injection.
What could go wrong: This is a very early, small study with only 40 healthy volunteers. It is not testing a treatment or vaccine, just measuring immune responses, so it may not lead to any practical application.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Infections infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INFECTION

Contacts and locations

Locations

Laboratoire d'anatomo-pathologie, hôpital Pasteur

Nice, 06000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.